AI制药，10大核心玩家！

TL;DR - A Chinese industry roundup profiling 10 overseas and 10 domestic "core players" in AI-driven drug discovery, arguing the sector is shifting from 1.0 (point tools bolted onto existing workflows) to 2.0 (full-pipeline integration spanning target discovery through trial design, patient enrollment, and commercialization), amid a 2026 wave of M&A and talent consolidation by Anthropic, Roche, and AstraZeneca.

• Platform archetypes diverge: structure/generative-model shops (Isomorphic Labs' IsoDDE on AlphaFold3, Chai Discovery's Chai-3 sold SaaS-style, Generate Biomedicines' Chroma), physics-hybrid designers (Relay's Dynamo cryo-EM + long-timescale MD, Iambic's NeuralPLexer/Enchant, Tandem's TandemViz), phenotypic industrialization (Recursion's RecursionOS + BioHive-2), and non-synthetic chemical space (Enveda's 400k+ natural-product metabolomics library).
• Clinical validation is the new proof point: Insilico's rentosertib (TNIK, IPF) entered Phase III in July 2026 with ~18 months from target to candidate; Generate's GB-0895 (TSLP) is in registrational Phase III; Relay's zovegalisib (mutant-selective PI3Kα) is in Phase III; Iambic claims 18–24 month design-to-candidate vs. an industry norm of 4–5 years.
• Capital and partnerships are heavily concentrated: Xaira's $1B seed, Chai's $400M Series C at $3.8B post (OpenAI participating), Generate's $400M Nasdaq IPO, Insilico's ~$7B in new potential deal value, and Huashen/Sanofi's cumulative >$4.4B in milestones — with NVIDIA appearing as both investor (Generate) and infrastructure partner (Owkin's OwkinZero).
• Domestic differentiation is in wet-lab and agentic closed loops: XtalPi pairs Multi-Agent "Genius Agents" with robotic labs (exported to JW Pharma in Korea), Metis/剂泰 targets AI delivery systems (NanoForge, HK$2.11B HKEX listing), and 深度智耀 applies multi-agent systems to clinical CRO work including digital-twin trial simulation that cleared PMDA in a single review round.